Company Filing History:
Years Active: 2021-2025
Title: Amin Li: Innovator in KRAS Mutant Protein Inhibition
Introduction
Amin Li, based in Beijing, China, is a distinguished inventor with a focus on biopharmaceutical innovations. With an impressive portfolio of six patents, he has made significant contributions to the field of medical research, particularly in the development of inhibitors targeting mutant proteins.
Latest Patents
Among Amin's latest patents are the KRAS mutant protein inhibitors. These patents cover a KRAS mutant protein inhibitor represented by a specific formula, along with a detailed composition that includes the inhibitor and its use in therapeutic applications. This work is of critical importance in the fight against various cancers driven by KRAS mutations.
Career Highlights
Amin Li is currently employed at Jacobio Pharmaceuticals Co., Ltd., where he leverages his expertise in molecular biology and pharmacology. His innovative work contributes to advancing treatments that could greatly benefit patients with challenging diseases associated with KRAS mutations.
Collaborations
Throughout his career, Amin has worked alongside talented professionals, including Sujing Li and Peng Wang. Their collaborative efforts continue to enhance the development of cutting-edge treatments and foster a culture of innovation within their organization.
Conclusion
Amin Li's contributions to the field of biopharmaceuticals through his patents highlight the importance of research and development in the fight against cancer. His dedication to innovation at Jacobio Pharmaceuticals Co., Ltd. showcases the potential of targeted therapies in transforming patient care.